百济神州多款商业化产品及新增适应症被纳入新版国家医保目录及首个商保创新药目录

Group 1 - The core announcement is that BeiGene has multiple commercialized products and new indications included in the National Medical Insurance Administration's 2025 drug catalogs [1] - The newly released commercial health insurance innovative drug catalog includes two products: Baihe'an (Zanidatamab injection) and Kaizebai (Daratumumab β injection), which are used for specific cancer treatments [1] - Baihe'an is indicated for patients with unresectable locally advanced or metastatic biliary tract cancer (BTC) with high HER2 expression (IHC3+) [1] - Kaizebai is indicated for high-risk and relapsed/refractory neuroblastoma patients [1]